A carregar...
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4–5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the k...
Na minha lista:
| Publicado no: | Memo |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Vienna
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5605578/ https://ncbi.nlm.nih.gov/pubmed/28989542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-017-0352-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|